Several preclinical studies have shown that TYMS expression levels are a key determinant for therapeutic responsiveness to fluorouracil, which is one of the most commonly used chemotherapy drugs for HCC [8–10]. The gene discussed is TYMS; the disease is hepatocellular carcinoma.